Stock Groups

Landos Biopharma on Its Way to Commercialization By TipRanks


© Reuters. Landos Biopharma is on its way to commercialization

Landos Biopharma (LABP shares) have gained 55.7% during the past six month, which is an impressive return on shareholders’ capital.

Stockholders should expect that the share price will continue to rise. This stock is my favorite. TipRanks has LABP stock chart information.

Landos Biopharma, a biopharmaceutical company based in Blacksburg (Virginia), is an innovative therapeutics developer and discoverer that are late-clinical stage. The company hopes to market them as treatments for autoimmune disorders.

Specifically, the company would like to commercialize pills as a treatment for ulcerative colitis, Crohn’s disease, and eosinophilic esophagitis, in addition to topical formulations for the treatment of skin diseases such as psoriasis and atopic dermatitis.

The Q2 Earnings report

Landos does not sell any products at this time, however, its second quarter ended with $4.1 million in net profit, thanks to an $18 million non-recurring cash payment.

It was paid for collaboration agreements that would allow the commercialization in China of Landos products.

Future Perspectives

Omilancor is a treatment that treats mild-to-moderate colitis.

According to Landos, two more clinical trials are likely to yield promising results in the first half of 2022.

Ulcerative colitis refers to chronic inflammation of large intestine walls.

Treatment considers the possible autoimmune cause of the disease as the reason for the condition. Like other inflammatory bowel diseases, ulcerative colitis may also be caused by an intestinal imbalance.

This is an extremely common metabolic disorder in industrialized countries. It is often associated with unhealthy lifestyles that are frequently seen in contemporary society. Here is the amazing catalyst that will allow Landos to continue his treatment.

Wall Street’s Take

Three Wall Street analysts issued price targets for LABP over the last three months. Landos Biopharma has an average price target for $31.33, which translates into 109.3% upside. An analyst consensus of a Strong Buy rating has been established based upon three Buy ratings.


Landos has reached the final stage of development for its candidate for chronic inflammation bowel disorders.

This is followed by its launch. The authority will approve the launch stage. The stock can be traded as a healthcare company in commercial stage if everything goes according to plan.

Potential upsides include an extraordinary increase in share prices

Disclosure: Alberto Abaterusso had no position in the securities listed in this article at the time it was published.

Disclaimer: This article is solely the author’s opinion and does not reflect the opinions of TipRanks and its affiliates. It should only be used for informational purposes. TipRanks does not warrant the accuracy, reliability or completeness of this information. This article is not intended to be interpreted as an offer or recommendation for the purchase or sale of securities. This article is not intended to provide advice on legal, professional investment or financial matters. TipRanks or its affiliates are not responsible for the contents of this article. Any action you take based on the information is your responsibility. TipRanks’ or any affiliates does not endorse this article or make it a recommendation. The past performance of TipRanks or its affiliates is not an indication of future prices, results, or performances.